...
search icon
beam-img

Beam Therapeutics Inc Share Price

BEAM
NSQ
$25.16
-$0.43
(-1.68%)
1D
Industry: Biotechnology Sector: Health Care

Beam Therapeutics Inc Analyst Forecast

Beam Therapeutics Inc Share Price Chart

Beam Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.61B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.66M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.17
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$13.53 L
$36.44 H
$25.16

About Beam Therapeutics Inc, Common Stock

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Beam Therapeutics Inc Stock Returns

Time FrameBEAMSectorS&P500
1-Week Return-3.58%-1.66%-0.96%
1-Month Return-8.35%-4.76%-2.3%
3-Month Return-4.62%-3.81%-2.15%
6-Month Return20.25%9.66%0.81%
1-Year Return2.11%4.4%20.8%
3-Year Return-24.2%19.83%72.98%
5-Year Return-73.01%30.13%68.06%
10-Year Return36.48%119.85%229.83%

Beam Therapeutics Inc Financials

Dec '21Dec '22Dec '23Dec '24Dec '255YR TREND
Total Revenue51.84M60.92M377.71M63.52M139.74M[{"date":"2021-12-31","value":13.73,"profit":true},{"date":"2022-12-31","value":16.13,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":16.82,"profit":true},{"date":"2025-12-31","value":37,"profit":true}]
Cost of Revenue232.13M311.59M437.38M367.56M22.29M[{"date":"2021-12-31","value":53.07,"profit":true},{"date":"2022-12-31","value":71.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":84.04,"profit":true},{"date":"2025-12-31","value":5.1,"profit":true}]
Gross Profit(180.29M)(250.67M)377.71M(304.04M)117.45M[{"date":"2021-12-31","value":-47.73,"profit":false},{"date":"2022-12-31","value":-66.37,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-80.5,"profit":false},{"date":"2025-12-31","value":31.1,"profit":true}]
Gross Margin(347.75%)(411.48%)100.00%(478.67%)84.05%[{"date":"2021-12-31","value":-347.75,"profit":false},{"date":"2022-12-31","value":-411.48,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-478.67,"profit":false},{"date":"2025-12-31","value":84.05,"profit":true}]
Operating Expenses212.18M87.81M554.19M111.53M501.14M[{"date":"2021-12-31","value":38.29,"profit":true},{"date":"2022-12-31","value":15.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":20.12,"profit":true},{"date":"2025-12-31","value":90.43,"profit":true}]
Operating Income(392.46M)(338.48M)(176.49M)(415.57M)(383.69M)[{"date":"2021-12-31","value":-39246500000,"profit":false},{"date":"2022-12-31","value":-33847900000,"profit":false},{"date":"2023-12-31","value":-17648500000,"profit":false},{"date":"2024-12-31","value":-41556800000,"profit":false},{"date":"2025-12-31","value":-38369300000,"profit":false}]
Total Non-Operating Income/Expense21.82M68.10M87.55M87.96M347.43M[{"date":"2021-12-31","value":6.28,"profit":true},{"date":"2022-12-31","value":19.6,"profit":true},{"date":"2023-12-31","value":25.2,"profit":true},{"date":"2024-12-31","value":25.32,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Pre-Tax Income(370.64M)(285.68M)(131.16M)(376.70M)(79.99M)[{"date":"2021-12-31","value":-37063800000,"profit":false},{"date":"2022-12-31","value":-28567800000,"profit":false},{"date":"2023-12-31","value":-13116100000,"profit":false},{"date":"2024-12-31","value":-37670300000,"profit":false},{"date":"2025-12-31","value":-7999200000,"profit":false}]
Income Taxes(29.28M)3.41M1.37M39.00K-[{"date":"2021-12-31","value":-858.59,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":40.06,"profit":true},{"date":"2024-12-31","value":1.14,"profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Income After Taxes(341.36M)(289.09M)(132.53M)(376.74M)-[{"date":"2021-12-31","value":-34136000000,"profit":false},{"date":"2022-12-31","value":-28908800000,"profit":false},{"date":"2023-12-31","value":-13252700000,"profit":false},{"date":"2024-12-31","value":-37674200000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}]
Income From Continuous Operations(370.64M)(289.09M)(313.67M)(376.74M)(79.99M)[{"date":"2021-12-31","value":-37063800000,"profit":false},{"date":"2022-12-31","value":-28908800000,"profit":false},{"date":"2023-12-31","value":-31367300000,"profit":false},{"date":"2024-12-31","value":-37674200000,"profit":false},{"date":"2025-12-31","value":-7999200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Net Income(370.64M)(289.09M)(132.53M)(376.74M)(79.99M)[{"date":"2021-12-31","value":-37063800000,"profit":false},{"date":"2022-12-31","value":-28908800000,"profit":false},{"date":"2023-12-31","value":-13252700000,"profit":false},{"date":"2024-12-31","value":-37674200000,"profit":false},{"date":"2025-12-31","value":-7999200000,"profit":false}]
EPS (Diluted)(5.94)(4.13)(1.90)(4.58)(1.01)[{"date":"2021-12-31","value":-594,"profit":false},{"date":"2022-12-31","value":-413,"profit":false},{"date":"2023-12-31","value":-190,"profit":false},{"date":"2024-12-31","value":-458,"profit":false},{"date":"2025-12-31","value":-101.21,"profit":false}]

Beam Therapeutics Inc Ratios

Beam Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

BEAM
Cash Ratio 12.85
Current Ratio 13.09

Beam Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BEAM
ROA (LTM) -18.55%
ROE (LTM) -8.11%

Beam Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BEAM
Debt Ratio Lower is generally better. Negative is bad. 0.16
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.84

Beam Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BEAM
Trailing PE NM
Forward PE NM
P/S (TTM) 18.65
P/B 2.15
Price/FCF NM
EV/R 11.20
EV/Ebitda NM

FAQs

What is Beam Therapeutics Inc share price today?

Beam Therapeutics Inc (BEAM) share price today is $25.16

Can Indians buy Beam Therapeutics Inc shares?

Yes, Indians can buy shares of Beam Therapeutics Inc (BEAM) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BEAM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Beam Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Beam Therapeutics Inc (BEAM) via the Vested app. You can start investing in Beam Therapeutics Inc (BEAM) with a minimum investment of $1.

How to invest in Beam Therapeutics Inc shares from India?

You can invest in shares of Beam Therapeutics Inc (BEAM) via Vested in three simple steps:

  • Click on Sign Up or Invest in BEAM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Beam Therapeutics Inc shares
What is Beam Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Beam Therapeutics Inc (BEAM) is $36.44. The 52-week low price of Beam Therapeutics Inc (BEAM) is $13.53.

What is Beam Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Beam Therapeutics Inc (BEAM) is

What is Beam Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Beam Therapeutics Inc (BEAM) is 2.15

What is Beam Therapeutics Inc dividend yield?

The dividend yield of Beam Therapeutics Inc (BEAM) is 0.00%

What is the Market Cap of Beam Therapeutics Inc?

The market capitalization of Beam Therapeutics Inc (BEAM) is $2.61B

What is Beam Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Beam Therapeutics Inc is BEAM

How Can Investors Use Beam Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Beam Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Beam Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Beam Therapeutics Inc shares for Indian investors?

When investing in Beam Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Beam Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Beam Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Beam Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Beam Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top